Antiretroviral therapies associated with lipoatrophy in HIV-infected women

AIDS Patient Care and STDs

Volumn 21, Issue 5, 2007, Pages 297-305

  Tien, Phyllis C ^a,b   Barrón, Yolanda ^c   Justman, Jessica E ^d   Hyman, Charles ^e   Cohen, Mardge H ^f   Young, Mary ^g   Kovacs, Andrea ^h   Cole, Stephen R ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Columbia University ^*  (United States)

^e STATE UNIVERSITY OF NEW YORK   (United States)

^f Jr Hospital of Cook County   (United States)

^g GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ARM CIRCUMFERENCE; ARTICLE; BODY WEIGHT; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPEDANCE; LIPOATROPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEGRO; STATISTICAL ANALYSIS; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; ANTHROPOMETRY; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; DIDANOSINE; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; PROSPECTIVE STUDIES;

EID: 34249708296     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.128     Document Type: Article

References (38)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-58.
2. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquir Immune Defic Syndr 2002;31:50-55.
3. Galli M, Cozzi Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy - The LipoICoNa study. Arch Intern Med 2002;162:2621-2628.
4. Heath K, Hogg R, Singer J, Chan K, O'Shaughnessy M and Montaner J. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002;30:440-147.
5. Mallal SA, John M, Moore CB, James IR and McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-1316.
6. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 2003;17:971-979.
7. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-1667.
8. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin InfectDis 2002;34:1397-1405.
9. FRAM Study Investigators. Fat distribution in men with HIV Infection. J Acquir Immune Defic Syndr 2005;40:121-131.
10. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13: 465-171.
11. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-239.
12. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38:1464-1470.
13. Hawkins T. Appearance-related side effects of HIV-1 treatment. AIDS Patient Care STDS 2006;20:6-18.
14. Corless IB, Kirksey KM, Kemppainen J, et al. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDs 2005;19: 577-586.
15. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449.
16. Engelhard P. Correction options for lipoatrophy in HIV-infected patients. AIDS Patient Care STDs 2006; 20:151-160.
17. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004;18:1029-1036.
18. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 2005;38:393-398.
19. Kotler DP, Rosenbaum K, Wang J Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:228-237.
20. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-1398.
21. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84:1932-1937.
22. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999;13:735-737.
23. Mercie P, Viallard JF, Thiebaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001;15:126-129.
24. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093-2099.
25. Lichtenstein K, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr 2003;32:48-56.
26. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001;357:592-598.
27. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
28. Galli M, Veglia F, Angarano G, et al. Gender Differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr 2003;34: 58-56.
29. Mulligan K, Anastos K, Justman J, et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2005;38:18-22.
30. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005;12:1013-1019.
31. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9:117-125.
32. National Center for Health Statistics. The Third National Health and Examination Survey Reference Manuals and Reports [CD-ROM]. 1996.
33. Kotler DP, Burastero S, Wang J, Pierson RN, Jr. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease. Am J Clin Nutr 1996;64: 489S-497S.
34. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of Longitudinal Data, 2nd ed. Oxford: Oxford University Press, 2002.
35. Tien PC, Cole SR, Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2003;34:461-466.
36. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999;21:107-113.
37. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997;25:937-938.
38. Dube MP, Zackin R, Tebas P et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384. Antivir Ther 2002:L18.